Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Ottawa, Canada Clinical Trials

A listing of Ottawa, Canada clinical trials actively recruiting patients volunteers.

RESULTS

Found (426) clinical trials

A Study Of Daratumumab Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide

This is a randomized phase II open label study of daratumumab, weekly low-dose oral cyclophosphamide and dexamethasone with or without pomalidomide in patients with relapsed and refractory multiple myeloma. The study consists of two arms. Patients will be randomized into ARM A and ARM B in a 1:1 ratio. In ...

Phase

0.0 miles

Learn More »

A Phase I/II Study of Concurrent Pemetrexed/Cisplatin/Radiation in Stage IIIA/B Non-Small Cell Lung Cancer

Concurrent chemoradiation is the accepted standard of care for most patients with unresectable stage III A/B non-small cell lung cancer (NSCLC) but no standard chemotherapy regimen or schedule has yet been established. Cisplatin, combined with a third generation agent, provides the greatest activity in advanced NSCLC but, to date, no ...

Phase

0.0 miles

Learn More »

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

All Medtronic market-released leads and all market-released IPG, ICD and CRT devices are eligible to be included in this study.

Phase N/A

0.0 miles

Learn More »

Study of BIIB092 in Participants With Progressive Supranuclear Palsy

This study, previously posted by Bristol-Myers Squibb, has transitioned to Biogen under a licensing agreement.

Phase

0.0 miles

Learn More »

An Efficacy Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

The drug being tested in this study is called Ixazomib. Ixazomib is being tested to treat people who have relapsed and/or refractory multiple myeloma (RRMM). This study will compare the efficacy and safety in participants who take ixazomib and dexamethasone to pomalidomide and dexamethasone. It is an open-label, phase 2 ...

Phase

0.0 miles

Learn More »

Remission and Flare in Psoriatic Arthritis: a Prospective 6-month Study With a Double Perspective.

Introduction: Psoriatic arthritis (PsA) is a heterogeneous chronic disease with a significant patient-perceived impact leading to pain, fatigue, impaired function and quality of life and psychological distress. Remission is the announced treatment target in PsA. Several definitions of remission have been proposed including definitions on composite scores such as the ...

Phase N/A

0.0 miles

Learn More »

Immunogenicity and Safety of Sci-B-Vac to Engerix-B in Adults 18 Years Old and Superiority in Adults 45 Years Old.

This study is a double-blind randomized controlled trial designed to establish the non-inferiority of Sci-B-Vac compared to Engerix-B in adults 18 years old and the superiority of Sci-B-Vac compared to Engerix-B in adults 45 years old. Study subjects will be randomized 1:1 to receive either a total of 3 injections ...

Phase

0.0 miles

Learn More »

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

The hypothesis is treatment with combination of I+VEN will result in longer PFS compared with G-Clb in participants with previously untreated chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) who meet International Workshop on CLL (iwCLL) treatment criteria. The study includes screening (30 days), treatment (from randomization until treatment discontinuation) ...

Phase

0.0 miles

Learn More »

DPX-Survivac and Checkpoint Inhibitor in DLBCL

This is a Phase 2, non-randomized, open-label, uncontrolled, efficacy and safety trial. Participants will receive 2 priming injections (0.5ml) of the DPX-Survivac vaccine 3 weeks apart on Study Days 7 and 28. In addition, up to 6 booster vaccinations (0.1ml) over the course of the study occurring on Study Days ...

Phase

0.0 miles

Learn More »

Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness

Bloodstream infections are a common and serious problem, affecting 15% of critically ill patients, increasing length of hospital stay by 2-3 weeks, adding $25,000-40,000 in excess hospital costs, and tripling the risk of death. At the same time, antibiotic overuse is also a common and serious problem, in that 30-50% ...

Phase N/A

0.0 miles

Learn More »